Literature DB >> 17569950

Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II.

L Vedolin1, I V D Schwartz, M Komlos, A Schuch, A C Puga, L L C Pinto, A P Pires, R Giugliani.   

Abstract

BACKGROUND AND
PURPOSE: There are no reliable markers to predict neurologic outcome of patients with mucopolysaccharidosis (MPS) II. We hypothesized that brain MR imaging and MR spectroscopy are useful in depicting features related to cognitive impairment (CI) in MPS II.
MATERIALS AND METHODS: Nineteen male patients with MPS II were included in this study. They were evaluated through intelligence/developmental tests to be classified in 2 groups: patients with CI (group A) or patients without CI (group B). Brain MR imaging evaluated white matter (WM) lesions, hydrocephalus, and brain atrophy. Voxels from MR spectroscopy (point-resolved spectroscopy TE 30 ms) were positioned in the WM of the deep right frontal lobe and at the gray matter (GM) in the posterior occipital cortex across the midline. Comparison of MR imaging and MR spectroscopy findings between these 2 groups and a control group was performed.
RESULTS: The mean age of the patients was 9.6 years (group A, 7.08 years old, 12 patients; group B, 14 years old, 7 patients; P = .076). Brain atrophy and hydrocephalus were more frequently found in group A patients (P=.006 and P=.029, respectively); these patients also presented more severe WM lesions than patients from group B (P=.022). Patients from group A also had a higher myo-inositol (mIns)/creatine (Cr) ratio in the GM (P=.046) and in the WM (P=.032). The choline/Cr and N-acetylaspartate/Cr ratios were similar in both groups.
CONCLUSIONS: Our study showed that severe WM lesions, brain atrophy, hydrocephalus, and elevated mIns/Cr were more common in patients with MPS II and with CI.

Entities:  

Mesh:

Year:  2007        PMID: 17569950      PMCID: PMC8134159          DOI: 10.3174/ajnr.A0510

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  33 in total

1.  Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy.

Authors:  Rachel Katz-Brull; Robert E Lenkinski; Renaud A Du Pasquier; Igor J Koralnik
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

2.  MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosis.

Authors:  Matilde Inglese; Annette O Nusbaum; Gregory M Pastores; John Gianutsos; Edwin H Kolodny; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

3.  Relationships between astrogliosis and 1H MR spectroscopic measures of brain choline/creatine and myo-inositol/creatine in a primate model.

Authors:  John P Kim; Margaret R Lentz; Susan V Westmoreland; Jane B Greco; Eva M Ratai; Elkan Halpern; Andrew A Lackner; Eliezer Masliah; R Gilberto González
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

Review 4.  Clinical applications of proton MR spectroscopy.

Authors:  M Castillo; L Kwock; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  1996-01       Impact factor: 3.825

5.  Evaluation of accumulated mucopolysaccharides in the brain of patients with mucopolysaccharidoses by (1)H-magnetic resonance spectroscopy before and after bone marrow transplantation.

Authors:  Y Takahashi; K Sukegawa; M Aoki; A Ito; K Suzuki; H Sakaguchi; M Watanabe; K Isogai; S Mizuno; H Hoshi; K Kuwata; S Tomatsu; S Kato; T Ito; N Kondo; T Orii
Journal:  Pediatr Res       Date:  2001-03       Impact factor: 3.756

Review 6.  Cellular pathology of lysosomal storage disorders.

Authors:  S U Walkley
Journal:  Brain Pathol       Date:  1998-01       Impact factor: 6.508

7.  MRI findings in the mild type of mucopolysaccharidosis II (Hunter's syndrome).

Authors:  S Shimoda-Matsubayashi; Y Kuru; H Sumie; T Ito; N Hattori; Y Okuma; Y Mizuno
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

8.  White matter changes mimicking a leukodystrophy in a patient with Mucopolysaccharidosis: characterization by MRI.

Authors:  Rita Barone; Enrico Parano; Rosario Rich Trifiletti; Agata Fiumara; Piero Pavone
Journal:  J Neurol Sci       Date:  2002-03-30       Impact factor: 3.181

9.  Cerebrospinal fluid shunts in the management of behavioural problems in Sanfilippo syndrome (MPS III).

Authors:  S P Robertson; G L Klug; J G Rogers
Journal:  Eur J Pediatr       Date:  1998-08       Impact factor: 3.183

10.  A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).

Authors:  Joseph Muenzer; James E Wraith; Michael Beck; Roberto Giugliani; Paul Harmatz; Christine M Eng; Ashok Vellodi; Rick Martin; Uma Ramaswami; Muge Gucsavas-Calikoglu; Suresh Vijayaraghavan; Susanne Wendt; Suzanne Wendt; Ana Cristina Puga; Antonio Puga; Brian Ulbrich; Marwan Shinawi; Maureen Cleary; Diane Piper; Anne Marie Conway; Ann Marie Conway; Alan Kimura
Journal:  Genet Med       Date:  2006-08       Impact factor: 8.822

View more
  22 in total

Review 1.  Brain and spinal MR imaging findings in mucopolysaccharidoses: a review.

Authors:  D I Zafeiriou; S P Batzios
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

2.  Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.

Authors:  Agnes Chen; Carole Vogler; Michael McEntee; Stephen Hanson; N Matthew Ellinwood; Jackie Jens; Elizabeth Snella; Merry Passage; Steven Le; Catalina Guerra; Patricia Dickson
Journal:  APMIS       Date:  2011-05-14       Impact factor: 3.205

Review 3.  Hydrocephalus and mucopolysaccharidoses: what do we know and what do we not know?

Authors:  Amauri Dalla Corte; Carolina F M de Souza; Maurício Anés; Roberto Giugliani
Journal:  Childs Nerv Syst       Date:  2017-06-07       Impact factor: 1.475

4.  Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II.

Authors:  Zheng Fan; M Styner; J Muenzer; M Poe; M Escolar
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-04       Impact factor: 3.825

5.  Closed Meningo(encephalo)cele: a new feature in Hunter syndrome.

Authors:  R Manara; E Priante; M Grimaldi; L Santoro; G Polonara; R Parini; M Scarpa
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-22       Impact factor: 3.825

Review 6.  Mucopolysaccharidoses: overview of neuroimaging manifestations.

Authors:  Manal Nicolas-Jilwan; Moeenaldeen AlSayed
Journal:  Pediatr Radiol       Date:  2018-05-11

7.  Features of brain MRI in dogs with treated and untreated mucopolysaccharidosis type I.

Authors:  Charles H Vite; Igor Nestrasil; Anton Mlikotic; Jackie K Jens; Elizabeth M Snella; William Gross; Elsa G Shapiro; Victor Kovac; James M Provenzale; Steven Chen; Steven Q Le; Shih-hsin Kan; Shida Banakar; Raymond Y Wang; Mark E Haskins; N Matthew Ellinwood; Patricia I Dickson
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

8.  Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution.

Authors:  Renzo Manara; Angelica Rampazzo; Mara Cananzi; Leonardo Salviati; Rodica Mardari; Paola Drigo; Rosella Tomanin; Nicoletta Gasparotto; Elena Priante; Maurizio Scarpa
Journal:  J Inherit Metab Dis       Date:  2010-01-06       Impact factor: 4.982

Review 9.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

Review 10.  Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed.

Authors:  S Al Sawaf; E Mayatepek; B Hoffmann
Journal:  J Inherit Metab Dis       Date:  2008-07-13       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.